जर्नल ऑफ़ क्लिनिकल एंड एक्सपेरिमेंटल पैथोलॉजी

अमूर्त

Secreted Clusterin (sCLU) Gene Silencing Enhances Chemosensitivity of A549 Cells to Cisplatin through AKT and ERK1/2 Pathways In Vitro

Mei Wang, Xiangchun Li and Zongxiu Yin

Several studies have shown Secreted Clusterin (sCLU) silencing directed against sCLU mRNA in sCLU-rich lung cancer cell lines sensitized cells to chemotherapy. However, the molecular mechanisms underlying the effect of sCLU silencing on lung cancer cell chemosensitivity is not known. In the present study, we aimed to determine that vector expressing short hairpin RNA against sCLU RNA (sCLU-shRNA) enhances the chemosensitivity in human small cell lung cancer A549 cells in vitro by inhibition of phosphorylated ERK1/2 (p-ERK1/2) and Akt (p-Akt). The pCDNA3, 1-sCLU and control scrambled pCDNA3. 1 plaismid was constructed. We investigated the effects of sCLU overexpression by pCDNA3. 1-sCLU transfection on chemosensitivity to cisplatin (DDP) in A549 cells in vitro. We down-regulated sCLU expression by short hairpin RNA against sCLU RNA (sCLU-shRNA) and investigated the effects on chemosensitivity to DDP in A549 cells and A549DDP in vitro. In order to confirm the correlation between sCLU and AKT and ERK1/2 signals, cells were treated with wortmannin and U0126. We found the chemotherapeutic agent DDP activated sCLU. Overexpression of sCLU increased cellular DDP chemoresistance in the A549DDP and pCDNA3. 1-sCLU transfected A549 cells via inhibition DDP-induced apoptosis.Whereas sCLU knockdown induced chemosensitization in the S549 and A549DDP cells via increase of DDP-induced apoptosis. sCLU overexpression activated pAkt Ser473 and pERK1/2Thr202/Tyr204, and vice versa. Inhibition of pAkt Ser473 and pERK1/2Thr202/Tyr204 was sufficient to induce significant recovery in chemosensitivity to DDP in A549DDP in the presence of sCLU overexpression. The chemotherapeutic agent DDP activated sCLU, which directly regulated pAkt and pERK1/2. This novel finding suggests that therapies directed against sCLU and its downstream signaling targets pAkt and pERK1/2 may have the potential to enhance the efficacy of DDP-based chemotherapy.